Earnings Call
Apr 30, 2026
Q1 FY2026
EPS Estimate
4.77
EPS Actual
5.15
Post-Earnings Close
$329.82
Earnings Reaction
-4.7%
Amgen's first quarter of 2026 delivered broad-based momentum across its portfolio, with six designated growth drivers collectively generating $5.6 billion in product sales, nearly 70% of the total, and growing 24% year-over-year. Overall product sales rose 4%, a figure that understates the underlying dynamism given the headwind from Prolia and XGEVA, which together fell 32% following loss of exclusivity and are expected to erode further through the year. The company raised full-year 2026 guidance, now targeting total revenues of $37.1 billion to $38.5 billion and non-GAAP EPS of $21.70 to $23.10, framing the year as a 'springboard' from which durable long-term growth is expected to emerge.
Report generated on May 4, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full AMGN analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.